BioCentury
ARTICLE | Clinical News

Big gain for MacroGenics after breast cancer readout

February 6, 2019 3:28 PM UTC

MacroGenics Inc. (NASDAQ:MGNX) shares leapt Wednesday after the company said margetuximab led to a survival benefit vs. Herceptin trastuzumab in the Phase III SOPHIA trial to treat HER2-positive metastatic breast cancer. MacroGenics is planning a BLA submission next half.

MacroGenics gained $14.49 (130%) to $25.60 Wednesday, lifting its market cap to over $1 billion. Founded in 2000, MacroGenics has no marketed products; margetuximab is its most advanced clinical candidate...

BCIQ Company Profiles

MacroGenics Inc.